Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1604)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1690)
  2. Survivorship Research (1193)
  3. Solid Tumor Oncology Division (1052)
  4. Department of Pathology and Laboratory Medicine (957)
  5. Surgery (947)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (698)
  2. Daniel Coit (543)
  3. Allan Halpern (401)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (89)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. American Journal of Surgical Pathology (64)

More Publications

Publishers
  1. Springer (341)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (162)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Squamous cell carcinoma in situ upstaging is not frequent in the nail unit: A tertiary cancer center experience
    Journal Article

    Aleissa, S.; Cowen, E.; Navarrete-Dechent, C.; Busam, K. J.; Rossi, A. M.; Lee, E. H.; Nehal, K. S.
    Archives of Dermatological Research (2022)

    Fulltext@MSK | Save
  • Spitz melanocytic tumours – A review
    Review

    Yeh, I.; Busam, K. J.
    Histopathology (2022)

    Fulltext@MSK | Save
  • Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos) – Associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients
    Research Letter

    Stoll, J. R.; Battle, L.; Moy, A.; Dusza, S. W.; Park, J. H.; Tallman, M. S.; Taylor, J.; Markova, A.
    Journal of the American Academy of Dermatology (2022)

    Fulltext@MSK | Save
  • Deep learning for basal cell carcinoma detection for reflectance confocal microscopy
    Journal Article

    Campanella, G.; Navarrete-Dechent, C.; Liopyris, K.; Monnier, J.; Aleissa, S.; Minhas, B.; Scope, A.; Longo, C.; Guitera, P.; Pellacani, G.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • Comparison of community pathologists with expert dermatopathologists evaluating Breslow thickness and histopathologic subtype in a large international population-based study of melanoma
    Research Letter

    Yardman-Frank, J. M.; Bronner, B.; Rosso, S.; From, L.; Busam, K.; Groben, P.; Tucker, P.; Cust, A.; Armstrong, B.; Kricker, A.; more...
    JAAD International (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
    Meeting Abstract

    Sacco, J.; Carvajal, R.; Butler, M.; Shoushtari, A.; Hassel, J.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients
    Meeting Abstract

    Knorr, D.; Ravetch, J.; D'Andrea, G.; Vahdat, L.; Klebanoff, C.; Robson, M.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors
    Meeting Abstract

    Kuryk, L.; Moller, A. S.; Kumar, S.; Shoushtari, A.; Ares, L. P.; Jaderberg, M.; Wiklund, E. D.; Levitsky, V.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save